These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 39102214)

  • 1. Next-generation vaccines are showing promise against glioblastoma.
    Dillman RO; Bota DA
    Oncotarget; 2024 Aug; 15():543-548. PubMed ID: 39102214
    [No Abstract]   [Full Text] [Related]  

  • 2. Vaccine-based immunotherapy for glioblastoma.
    Thomas AA; Fisher JL; Ernstoff MS; Fadul CE
    CNS Oncol; 2013 Jul; 2(4):331-49. PubMed ID: 25054578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in Immunotherapy for Glioblastoma Multiforme.
    Huang B; Zhang H; Gu L; Ye B; Jian Z; Stary C; Xiong X
    J Immunol Res; 2017; 2017():3597613. PubMed ID: 28299344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cell immunotherapy for glioblastoma.
    Polyzoidis S; Ashkan K
    Expert Rev Anticancer Ther; 2014 Jul; 14(7):761-3. PubMed ID: 24850137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cell vaccines to combat glioblastoma.
    Wheeler CJ
    Expert Rev Neurother; 2010 Apr; 10(4):483-6. PubMed ID: 20367199
    [No Abstract]   [Full Text] [Related]  

  • 6. [II. Autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma].
    Maruyama T; Muragaki Y; Ishikawa E; Nitta M; Saito T; Ohno T; Iseki H; Okada Y
    Gan To Kagaku Ryoho; 2015 Jun; 42(6):683-6. PubMed ID: 26242005
    [No Abstract]   [Full Text] [Related]  

  • 7. Should dendritic cell-based tumor vaccination be incorporated into standard therapy for newly diagnosed glioblastoma patients?
    Van Gool S; De Vleeschouwer S
    Expert Rev Neurother; 2012 Oct; 12(10):1173-6. PubMed ID: 23082731
    [No Abstract]   [Full Text] [Related]  

  • 8. Current vaccine trials in glioblastoma: a review.
    Xu LW; Chow KK; Lim M; Li G
    J Immunol Res; 2014; 2014():796856. PubMed ID: 24804271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study.
    Heimberger AB; Sun W; Hussain SF; Dey M; Crutcher L; Aldape K; Gilbert M; Hassenbusch SJ; Sawaya R; Schmittling B; Archer GE; Mitchell DA; Bigner DD; Sampson JH
    Neuro Oncol; 2008 Feb; 10(1):98-103. PubMed ID: 18079360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenging Hurdles of Current Targeting in Glioblastoma: A Focus on Immunotherapeutic Strategies.
    Genoud V; Migliorini D
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33800593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine for aggressive brain tumors may prolong survival.
    Health News; 2004 Dec; 10(12):7. PubMed ID: 15645564
    [No Abstract]   [Full Text] [Related]  

  • 12. Promising vaccines for treating glioblastoma.
    Swartz AM; Shen SH; Salgado MA; Congdon KL; Sanchez-Perez L
    Expert Opin Biol Ther; 2018 Nov; 18(11):1159-1170. PubMed ID: 30281978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapeutic vaccination for glioblastoma].
    Dietrich PY; Dutoit V
    Med Sci (Paris); 2020 Apr; 36(4):319-322. PubMed ID: 32356704
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunotherapy trials for glioblastoma multiforme: promise and pitfalls.
    Yong RL; Lonser RR
    World Neurosurg; 2012; 77(5-6):636-8. PubMed ID: 22120230
    [No Abstract]   [Full Text] [Related]  

  • 15. PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma.
    Oh T; Ivan ME; Sun MZ; Safaee M; Fakurnejad S; Clark AJ; Sayegh ET; Bloch O; Parsa AT
    Immunotherapy; 2014; 6(6):737-53. PubMed ID: 25186604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First results on the DCVax phase III trial: raising more questions than providing answers.
    Wick W; van den Bent MJ
    Neuro Oncol; 2018 Sep; 20(10):1283-1284. PubMed ID: 30137551
    [No Abstract]   [Full Text] [Related]  

  • 17. Cellular-based immunotherapies for patients with glioblastoma multiforme.
    Xu X; Stockhammer F; Schmitt M
    Clin Dev Immunol; 2012; 2012():764213. PubMed ID: 22474481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized neoantigen vaccines: a glimmer of hope for glioblastoma.
    Londhe VY; Date V
    Expert Rev Vaccines; 2020 May; 19(5):407-417. PubMed ID: 32238056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients.
    Paff M; Alexandru-Abrams D; Hsu FP; Bota DA
    Hum Vaccin Immunother; 2014; 10(11):3322-31. PubMed ID: 25625931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End.
    Datsi A; Sorg RV
    Front Immunol; 2021; 12():770390. PubMed ID: 34795675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.